A previous study revealed that intracellular PD‐L1 is able to act as an RNA‐binding protein to protect the mRNA of DDR‐related genes from degradation, thereby increasing tumor resistance to DNA damage and leading to radiotherapy resistance.[6a] In addition, radiotherapy can lead to the upregulation of PD‐L1 expression in tumor cells, weakening the effect of immunotherapy.[23] Previous studies have confirmed that TPP‐LND@Lip was capable of down‐regulating the expression of PD‐L1 in vivo and in vitro effectively (Figure 4). Here, CD274 is linked to neoplasm.